Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 43Metastatic Castration-resistant Prostate Cancer 5Prostatic Diseases 3Kidney Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Carcinoma, Renal Cell 2Thrombocytopenia 1Renal Insufficiency 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Diseases, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1

Interventions

padeliporfin 5darolutamide 3Pluvicto 3gallium 68 PSMA-11 2enzalutamide 2apalutamide 2Radiotherapy 2Nivolumab 2Androgen Antagonists 2Abiraterone Acetate 2talazoparib 1sipuleucel-T 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gedatolisib 1abiraterone 1Therapeutics 1Tamsulosin 1Surveys and Questionnaires 1Standard of Care 1Robotic Surgical Procedures 1Prostate-Specific Antigen 1Prednisone 1Paclitaxel 1Oxygen 1Nitrous Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Diseases × Pluvicto × Clear all
NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

NCT05150236 2023-12-15

ANZUP2001

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
93 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡